The T1D Fund: A Breakthrough T1D Venture
We are an innovative venture philanthropy fund that drives investments toward cures for type 1 diabetes.
A Fund unlike any other
The T1D Fund is one of the largest, most successful funds of its kind in the world and the only one focused on T1D.
In 2016, a group of volunteers identified the need to attract more private investment to drive the development of type 1 diabetes cures. Their vision resulted in the T1D Fund, an impact investment fund that has used a venture philanthropic approach to catalyze more than $900 million in investments in our mission and has transformed the life sciences market for T1D.
Through its investments in partnership with private capital, including venture capital, corporations, an foundations, the T1D Fund seeks to attract the private investment necessary to advance cures for type 1 diabetes.
The Fund is going to be the key to finding a cure much more quickly.”
About the T1D Fund
Read more about the T1D Fund, the only venture philanthropy fund in the world focused on T1D.
We leverage philanthropic capital to build a portfolio of investments that are attractive to investors and are compelling to the T1D community.
Learn about our portfolio companies focused on improving lives, cell therapies, and disease-modifying therapies.
As a venture philanthropy fund, we approach investment opportunities slightly differently than either a venture capital fund or a non-profit organization.
Our Board of Directors, Investment Committee, and Partners and Advisors include experts in the financial and research fields.
The relationship between Breakthrough T1D and the T1D Fund
The T1D Fund is Breakthrough T1D’s key to commercial opportunities. We leverage Breakthrough T1D’s expertise in the T1D ecosystem through its deep network and expertise in research and advocacy. This helps us invest with great potential for impact; bring the knowledge and network of T1D stakeholders and industry dynamics to benefit the broader life sciences investment community; and support companies motivated to develop therapies for T1D. The Fund is Breakthrough T1D’s venture investment entity, governed by a distinct board.
